Cantor Fitzgerald Research Analysts Lower Earnings Estimates for Fennec Pharmaceuticals Inc. (TSE:FRX)

Fennec Pharmaceuticals Inc. (TSE:FRX – Get Rating) – Stock analysts at Cantor Fitzgerald decreased their FY2023 earnings per share estimates for shares of Fennec Pharmaceuticals in a note issued to investors on Monday, May 15th. Cantor Fitzgerald analyst C. Duncan now expects that the biopharmaceutical company will post earnings per share of ($0.69) for the year, down from their prior estimate of ($0.63). The consensus estimate for Fennec Pharmaceuticals’ current full-year earnings is $0.08 per share.

Fennec Pharmaceuticals (TSE:FRX – Get Rating) last announced its quarterly earnings results on Thursday, March 30th. The biopharmaceutical company reported C($0.35) EPS for the quarter, missing analysts’ consensus estimates of C($0.33) by C($0.02).

Fennec Pharmaceuticals Price Performance

Shares of Fennec Pharmaceuticals stock opened at C$10.14 on Wednesday. The company has a debt-to-equity ratio of 881.09, a current ratio of 5.80 and a quick ratio of 10.17. The business’s 50 day simple moving average is C$11.05 and its two-hundred day simple moving average is C$12.17. The stock has a market capitalization of C$267.90 million, a P/E ratio of -8.52 and a beta of 0.16. Fennec Pharmaceuticals has a one year low of C$6.70 and a one year high of C$14.41.

About Fennec Pharmaceuticals

(Get Rating)

Fennec Pharmaceuticals Inc operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc and changed its name to Fennec Pharmaceuticals Inc in September 2014.